Guanfacine Extended Release

DRUG4 trials

Sponsors

The University of Texas Health Science Center at San Antonio, JPM van Stralen Medicine Professional, UConn Health, Maimonides Medical Center

Conditions

Abnormalities, MultipleAggressionAntihypertensive AgentsAttention Deficit Disorder With HyperactivityAttention Deficit Hyperactivity DisorderBehavioral SymptomsChromosome DisordersCongenital Abnormalities

Phase 4

Electrophysiological Effects of Guanfacine Extended Release in Attention Deficit Hyperactivity Disorder (ADHD)

CompletedNCT01069523

The University of Texas Health Science Center at San AntonioAttention Deficit Disorder With Hyperactivity

Start: 2010-03-31End: 2011-08-31Updated: 2012-09-03

Efficacy of GXR as Adjunctive Therapy With Psycho-stimulant on Executive Function in Children With ADHD

CompletedNCT01985581

JPM van Stralen Medicine ProfessionalAttention Deficit Hyperactivity Disorder

Start: 2013-10-31End: 2015-03-31Updated: 2016-05-23

Guanfacine Extended Release and Mindfulness Skills Therapy

WithdrawnNCT03258476

UConn HealthStress Disorder

Start: 2019-03-01End: 2019-12-03Updated: 2021-03-08

Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome

CompletedNCT05657860

Maimonides Medical CenterAbnormalities, Multiple, Aggression, Antihypertensive Agents +18

Start: 2020-12-17End: 2023-12-16Updated: 2024-08-19